Show simple item record

dc.contributor.authorRenehan, Andrew G
dc.contributor.authorFrystyk, Jan
dc.contributor.authorHowell, Anthony
dc.contributor.authorO'Dwyer, Sarah T
dc.contributor.authorShalet, Stephen M
dc.contributor.authorFlyvbjerg, Allan
dc.date.accessioned2009-06-19T13:46:12Z
dc.date.available2009-06-19T13:46:12Z
dc.date.issued2007-06
dc.identifier.citationThe effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. 2007, 17 (3):210-9 Growth Horm. IGF Res.en
dc.identifier.issn1096-6374
dc.identifier.pmid17360217
dc.identifier.doi10.1016/j.ghir.2007.01.017
dc.identifier.urihttp://hdl.handle.net/10541/71040
dc.description.abstractBACKGROUND: Oral estrogen alone (EA) decreases concentrations of total IGF-I while increasing IGFBP-1, but data on other IGF-related peptides are inconsistent and/or sparse. Combined oral estrogen and progestin (EP) may have differential effects on IGF-related peptides dependent on its progestin-associated androgenic activity. The aim of this study was to clarify these relationships, as circulating IGF-related peptides are potential surrogates of predisposition to common chronic diseases. DESIGN: Using an open-labelled cross-sectional design within a bowel cancer screening trial (aged 55-64 years), we determined total IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in fasted serum from 210 healthy women and free IGF-I (by ultrafiltration), insulin, IGFBP-1 and IGFBP-1:IGF-I binary complex in a selected subset of 92 women. Unadjusted and adjusted (using generalized linear models) means were compared. RESULTS: Among EA users, mean concentrations for total IGF-I (adjusted P=0.004) and free IGF-I (P<0.001) were reduced, whereas mean concentrations of IGFBP-1 (P=0.001) and binary complex (P=0.01) were increased compared with non-users. Taken as a whole group, EP use was not associated with differences in concentrations of IGF-related peptides, but on sub-group analyses, mean concentrations associated with the use of progestins with reduced androgenic activity reflected the use of EA. By contrast, mean IGFBP-2 concentrations were significantly reduced among both EA (P=0.008) and EP (P=0.002) users, irrespective of androgenic activity. Neither EA nor EP influenced mean concentrations of IGF-II, insulin and IGFBP-3. CONCLUSIONS: The uses of oral sex steroid replacements are associated with significant changes in several IGF-related analytes in a preparation-specific manner, suggesting different regulatory mechanisms. However, the directions of these changes do not fit simple correlative models of predisposition to common diseases.
dc.language.isoenen
dc.subject.meshDisease
dc.subject.meshDisease Susceptibility
dc.subject.meshDrug Therapy, Combination
dc.subject.meshEstrogen Replacement Therapy
dc.subject.meshEstrogens
dc.subject.meshFemale
dc.subject.meshGonadal Steroid Hormones
dc.subject.meshHormone Replacement Therapy
dc.subject.meshHumans
dc.subject.meshInsulin-Like Growth Factor Binding Proteins
dc.subject.meshMiddle Aged
dc.subject.meshPeptides
dc.subject.meshProgestins
dc.subject.meshSomatomedins
dc.titleThe effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. arenehan@picr.man.ac.uken
dc.identifier.journalGrowth Hormone & IGF Researchen
html.description.abstractBACKGROUND: Oral estrogen alone (EA) decreases concentrations of total IGF-I while increasing IGFBP-1, but data on other IGF-related peptides are inconsistent and/or sparse. Combined oral estrogen and progestin (EP) may have differential effects on IGF-related peptides dependent on its progestin-associated androgenic activity. The aim of this study was to clarify these relationships, as circulating IGF-related peptides are potential surrogates of predisposition to common chronic diseases. DESIGN: Using an open-labelled cross-sectional design within a bowel cancer screening trial (aged 55-64 years), we determined total IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in fasted serum from 210 healthy women and free IGF-I (by ultrafiltration), insulin, IGFBP-1 and IGFBP-1:IGF-I binary complex in a selected subset of 92 women. Unadjusted and adjusted (using generalized linear models) means were compared. RESULTS: Among EA users, mean concentrations for total IGF-I (adjusted P=0.004) and free IGF-I (P<0.001) were reduced, whereas mean concentrations of IGFBP-1 (P=0.001) and binary complex (P=0.01) were increased compared with non-users. Taken as a whole group, EP use was not associated with differences in concentrations of IGF-related peptides, but on sub-group analyses, mean concentrations associated with the use of progestins with reduced androgenic activity reflected the use of EA. By contrast, mean IGFBP-2 concentrations were significantly reduced among both EA (P=0.008) and EP (P=0.002) users, irrespective of androgenic activity. Neither EA nor EP influenced mean concentrations of IGF-II, insulin and IGFBP-3. CONCLUSIONS: The uses of oral sex steroid replacements are associated with significant changes in several IGF-related analytes in a preparation-specific manner, suggesting different regulatory mechanisms. However, the directions of these changes do not fit simple correlative models of predisposition to common diseases.


Files in this item

This item appears in the following Collection(s)

Show simple item record